Vivos Therapeutics (VVOS) Expected to Announce Earnings on Wednesday

Vivos Therapeutics (NASDAQ:VVOS) is expected to issue its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $5.47 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 5:00 PM ET.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.10. The business had revenue of $5.15 million during the quarter, compared to analysts’ expectations of $5.63 million. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%. On average, analysts expect Vivos Therapeutics to post ($1.30) EPS for the current fiscal year and ($0.10) EPS for the next fiscal year.

Vivos Therapeutics Trading Down 9.9%

Shares of VVOS stock opened at $0.09 on Wednesday. The firm has a fifty day moving average price of $0.14 and a 200 day moving average price of $0.69. The company has a market cap of $1.74 million, a P/E ratio of -0.05 and a beta of 6.37. Vivos Therapeutics has a 12 month low of $0.09 and a 12 month high of $2.72.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $2.80.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.